Skip to main content
SpringerLink
Log in

Semaglutid zur Behandlung der nichtalkoholischen Steatohepatitis

Semaglutide for the treatment of nonalcoholic steatohepatitis

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679–690

    Article  CAS  Google Scholar 

  2. Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M (2020) Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1‑3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 46(2):100–109

    Article  CAS  Google Scholar 

  3. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547–1554

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für klinische Diabetologie, Deutsches Diabetes-Zentrum an der Heinrich-Heine-Universität, Leibniz-Zentrum für Diabetesforschung, Auf’m Hennekamp 65, 40225, Düsseldorf, Deutschland

    Sabine Kahl

Authors
  1. Sabine Kahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabine Kahl.

Ethics declarations

Interessenkonflikt

S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kahl, S. Semaglutid zur Behandlung der nichtalkoholischen Steatohepatitis. Diabetologe 17, 220–222 (2021). https://doi.org/10.1007/s11428-021-00733-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-021-00733-z

Search

Navigation